Haitao Pan - Publications

2017 Biostatistics The University of Texas MD Anderson Cancer Center/UTHealth Graduate School of Biomedical Sciences 
 2017- Biostatistics St. Jude's Research Hospital 
Bayesin statistics, clinical trials

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Li C, Sun H, Cheng C, Tang L, Pan H. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs. Contemporary Clinical Trials Communications. 30: 100990. PMID 36203850 DOI: 10.1016/j.conctc.2022.100990  0.351
2022 Su X, Li Y, Müller P, Hsu CW, Pan H, Do KA. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics. PMID 35748220 DOI: 10.1002/pst.2249  0.418
2022 Wu J, Pan H, Hsu CW. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints. Biometrical Journal. Biometrische Zeitschrift. PMID 35661226 DOI: 10.1002/bimj.202100305  0.357
2021 Mu R, Hu Z, Xu G, Pan H. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. Bmc Medical Research Methodology. 21: 278. PMID 34895153 DOI: 10.1186/s12874-021-01455-y  0.348
2021 Mu R, Xu G, Liu G, Pan H. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemporary Clinical Trials. 106504. PMID 34303862 DOI: 10.1016/j.cct.2021.106504  0.423
2021 Wu J, Pan H, Hsu CW. Bayesian single-arm phase II trial designs with time-to-event endpoints. Pharmaceutical Statistics. PMID 34085764 DOI: 10.1002/pst.2143  0.337
2020 Mu R, Pan H, Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Statistics in Medicine. PMID 33094528 DOI: 10.1002/sim.8780  0.319
2020 Li C, Pan H. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. Plos One. 15: e0237254. PMID 32853204 DOI: 10.1371/Journal.Pone.0237254  0.463
2020 Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharmaceutical Statistics. PMID 32248647 DOI: 10.1002/Pst.2013  0.55
2020 Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials. 105972. PMID 32151751 DOI: 10.1016/J.Cct.2020.105972  0.522
2020 Yan F, Zhang L, Zhou Y, Pan H, Liu S, Yuan Y. BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs Journal of Statistical Software. 94. DOI: 10.18637/jss.v094.i13  0.321
2018 Wu K, Pan H, Li C, Zhao Q, Wang L, Xia J. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. Plos One. 13: e0208354. PMID 30521581 DOI: 10.1371/Journal.Pone.0208354  0.316
2018 Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine. PMID 29682777 DOI: 10.1002/Sim.7674  0.545
2018 Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2  0.402
2017 Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 979-996. PMID 29249839 DOI: 10.1111/Rssc.12204  0.473
2017 Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. Journal of Cancer. 8: 3242-3250. PMID 29158796 DOI: 10.7150/Jca.20835  0.33
2016 Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine. PMID 27027650 DOI: 10.1002/Sim.6933  0.503
2016 Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine. PMID 26991076 DOI: 10.1002/Sim.6941  0.513
2015 Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442  0.515
2014 Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. Plos One. 9: e98147. PMID 24875783 DOI: 10.1371/Journal.Pone.0098147  0.456
2014 Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials (London, England). 11: 49-59. PMID 24137041 DOI: 10.1177/1740774513500081  0.386
2014 Pan H, Li C, Wang L, Jiang Z, Xia J. A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies Communications in Statistics - Simulation and Computation. 43: 254-268. DOI: 10.1080/03610918.2012.700365  0.449
2013 Pan H, Huang P, Wang Z, Wang L, Li C, Xia J. A novel Bayesian seamless phase I/II design. Plos One. 8: e73060. PMID 24023809 DOI: 10.1371/Journal.Pone.0073060  0.457
Show low-probability matches.